NF-kB inhibitor blocks B cell development at two checkpoints

Medical Immunology

Volumn 3, Issue , 2004, Pages

  Feng, Biao ^a   Cheng, Shuhua ^a   Pear, Warren S ^b   Liou, Hsiou Chi ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

B cell development; Bcl X; IkBa; NF kB; Retroviral gene transduction

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL X;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL COUNT; CELL FRACTIONATION; CELL MATURATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETIC CODE; GENETIC TRANSFECTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MOLECULAR MECHANICS; MOUSE; NONHUMAN;

EID: 2942598309     PISSN: 14769433     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-9433-3-1     Document Type: Article

References (66)

1. Nowell PC: Inhibition of human leukocyte mitosis by prednisolone in vitro. Cancer Res 1961, 21:1518-1521.
2. Gillis S, Crabtree GR, Smith KA: Glucocorticoid-induced inhibition of T cell growth factor production. I. The effect on mitogen-induced lymphocyte proliferation. J Immunol 1979, 123:1624-1631.
3. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin A. S., Jr.: Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995, 270:283-286.
4. Ray A, Prefontaine KE: Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci U S A 1994, 91:752-756.
5. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin A. S., Jr.: Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol 1995, 15:943-953.
6. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995, 270:286-290.
7. Adcock IM: Glucocorticoid-regulated transcription factors. Pulm Pharmacol Ther 2001, 14:211-219.
8. Liou HC, Hsia CY: Distinctions between c-Rel and other NF-kappaB proteins in immunity and disease. Bioessays 2003, 25:767-780.
9. Loder F, Mutschler B, Ray RJ, Paige CJ, Sideras P, Torres R, Lamers MC, Carsetti R: B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med 1999, 190:75-89.
10. Su TT, Rawlings DJ: Transitional B lymphocyte subsets operate as distinct checkpoints in murine splenic B cell development. J Immunol 2002, 168:2101-2110.
11. Allman D, Lindsley RC, DeMuth W, Rudd K, Shinton SA, Hardy RR: Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol 2001, 167:6834-6840.
12. Chung JB, Sater RA, Fields ML, Erikson J, Monroe JG: CD23 defines two distinct subsets of immature B cells which differ in their responses to T cell help signals. Int Immunol 2002, 14:157-166.
13. Mackay F, Browning JL: BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002, 2:465-475.
14. Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S: Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000, 192:953-964.
15. Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP: Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002, 168:5993-5996.
16. Hatada EN, Do RK, Orlofsky A, Liou HC, Prystowsky M, MacLennan IC, Caamano J, Chen-Kiang S: NF-kappaB1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappaB2 p100 to p52 in quiescent mature B cells. J Immunol 2003, 171:761-768.
17. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, Browning JL, Mackay F: BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000, 192:1453-1466.
18. Kitamura D, Roes J, Kuhn R, Rajewsky K: A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 1991, 350:423-426.
19. Reichlin A, Hu Y, Meffre E, Nagaoka H, Gong S, Kraus M, Rajewsky K, Nussenzweig MC: B cell development is arrested at the immature B cell stage in mice carrying a mutation in the cytoplasmic domain of immunoglobulin beta. J Exp Med 2001, 193:13-23.
20. Meffre E, Nussenzweig MC: Deletion of immunoglobulin beta in developing B cells leads to cell death. Proc Natl Acad Sci U S A 2002, 99:11334-11339.
21. Lam KP, Kuhn R, Rajewsky K: In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997, 90:1073-1083.
22. Niiro H, Clark EA: Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2002, 2:945-956.
23. Ghosh S, Karin M: Missing pieces in the NF-kappaB puzzle. Cell 2002, 109 Suppl:S81-96.
24. Karin M, Lin A: NF-kappaB at the crossroads of life and death. 2002.
25. Karin M, Delhase M: The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol 2000, 12:85-98.
26. Claudio E, Brown K, Park S, Wang H, Siebenlist U: BAFF-induced NEMO-independent processing of NF-kappaB2 in maturing B cells. Nat Immunol 2002, 3:958-965.
27. Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, French DM, Grewal IS, Cochran AG, Gordon NC, Yin J, Starovasnik MA, Dixit VM: BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002, 17:515-524.
28. Liou HC, Sha WC, Scott ML, Baltimore D: Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation. Mol Cell Biol 1994, 14:5349-5359.
29. Horwitz BH, Scott ML, Cherry SR, Bronson RT, Baltimore D: Failure of lymphopoiesis after adoptive transfer of NF-kappaB-deficient fetal liver cells. Immunity 1997, 6:765-772.
30. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U: Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 1997, 11:3482-3496.
31. Franzoso G, Carlson L, Poljak L, Shores EW, Epstein S, Leonardi A, Grinberg A, Tran T, Scharton-Kersten T, Anver M, Love P, Brown K, Siebenlist U: Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med 1998, 187:147-159.
32. Claudio E, Brown K, Park S, Wang H, Siebenlist U: BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 2002, 3:958-965.
33. Grossmann M, Metcalf D, Merryfull J, Beg A, Baltimore D, Gerondakis S: The combined absence of the transcription factors Rel and RelA leads to multiple hemopoietic cell defects. Proc Natl Acad Sci U S A 1999, 96:11848-11853.
34. Grossmann M, O'Reilly LA, Gugasyan R, Strasser A, Adams JM, Gerondakis S: The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. Embo J 2000, 19:6351-6360.
35. Pohl T, Gugasyan R, Grumont RJ, Strasser A, Metcalf D, Tarlinton D, Sha W, Baltimore D, Gerondakis S: The combined absence of NF-kappa B1 and c-Rel reveals that overlapping roles for these transcription factors in the B cell lineage are restricted to the activation and function of mature cells. Proc Natl Acad Sci U S A 2002, 99:4514-4519.
36. Grumont RJ, Rourke IJ, O'Reilly LA, Strasser A, Miyake K, Sha W, Gerondakis S: B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J Exp Med 1998, 187:663-674.
37. Cariappa A, Liou HC, Horwitz BH, Pillai S: Nuclear factor kappa B is required for the development of marginal zone B lymphocytes. J Exp Med 2000, 192:1175-1182.
38. Shaffer AL, Peng A, Schlissel MS: In vivo occupancy of the kappa light chain enhancers in primary pro- and pre-B cells: a model for kappa locus activation. Immunity 1997, 6:131-143.
39. Pui JC, Allman D, Xu L, DeRocco S, Karnell FG, Bakkour S, Lee JY, Kadesch T, Hardy RR, Aster JC, Pear WS: Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 1999, 11:299-308.
40. Izon DJ, Punt JA, Xu L, Karnell FG, Allman D, Myung PS, Boerth NJ, Pui JC, Koretzky GA, Pear WS: Notch1 regulates maturation of CD4+ and CD8+ thymocytes by modulating TCR signal strength. Immunity 2001, 14:253-264.
41. Tumang JR, Owyang A, Andjelic S, Jin Z, Hardy RR, Liou M-L, Liou HC: C-Rel is essential for B lymphocyte survival and cell cycle progression. Eur. J. Immunol. 1998, 28:4299-4312.
42. Pear WS, Nolan GP, Scott ML, Baltimore D: Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 1993, 90:8392-8396.
43. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr: NFkB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
44. Zong W-X, Edelstein LC, Chen C, Bash J, Gelinas C: The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kB that blocks TNF-induced apoptosis. Genes & Dev. 1999, 13:382-387.
45. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G: NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci U S A 1999, 96:9136-9141.
46. Grumont RJ, Rourke IJ, Gerondakis S: Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev 1999, 13:400-411.
47. Owyang AM, Tumang JR, Schram BR, Hsia CY, Behrens TW, Rothstein TL, Liou HC: c-Rel is required for the protection of B cells from antigen receptor- mediated, but not Fas-mediated, apoptosis. J Immunol 2001, 167:4948-4956.
48. Pizzi M, Goffi F, Boroni F, Benarese M, Perkins SE, Liou HC, Spano P: Opposing roles for NF-kappa B/Rel factors p65 and c-Rel in the modulation of neuron survival elicited by glutamate and interleukin- 1beta. J Biol Chem 2002, 277:20717-20723.
49. Hsia CY, Cheng S, Owyang AM, Dowdy SF, Liou HC: c-Rel regulation of the cell cycle in primary mouse B lymphocytes. Int Immunol 2002, 14:905-916.
50. Cheng S, Hsia CY, Leone G, Liou H-C: Cyclin E and Bcl-xL cooperatively induce cell cycle progression in c-Rel-/- B cells. Oncogene 2003, in press:.
51. Grumont RJ, Rourke IS, O' Reilly ZA, Strasser A, Miyake K, Sha W, Gerondakis S: B Lymphocytes differentially use the Rel and nuclear factor Kappa β1 (NF-kappaβ1) transcription factor to replicate cell cycle progression and apoptosis in quiescent and nitrogen activated cells. J EXP Med 1998, 187:663-674.
52. Burkly L, Hession C, Ogata L, Reilly C, Marconi LA, Olson D, Tizard R, Cate R, Lo D: Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 1995, 373:531-536.
53. Wu L, D'Amico A, Winkel KD, Suter M, Lo D, Shortman K: RelB is essential for the development of myeloid-related CD8alphadendritic cells but not of lymphoid-related CD8alpha+ dendritic cells. Immunity 1998, 9:839-847.
54. Weih F, Carrasco D, Bravo R: Constitutive and inducible Rel/NF-kappa B activities in mouse thymus and spleen. Oncogene 1994, 9:3289-3297.
55. Ouaaz F, Arron J, Zheng Y, Choi Y, Beg AA: Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 2002, 16:257-270.
56. Boffa D, Feng B, Sharma V, Dematteo R, Suthanthiran M, Nunez R, Liou H-C: Selective loss of c-Rel compromises dendritic cell activation of T lymphocytes. Cell. Immunol. 2003, In press:.
57. Grillot DA, Merino R, Pena JC, Fanslow WC, Finkelman FD, Thompson CB, Nunez G: bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. J Exp Med 1996, 183:381-391.
58. Fang W, Weintraub BC, Dunlap B, Garside P, Pape KA, Jenkins MK, Goodnow CC, Mueller DL, Behrens TW: Self-reactive B lymphocytes overexpressing Bcl-xL escape negative selection and are tolerized by clonal anergy and receptor editing. Immunity 1998, 9:35-45.
59. Turner M, Gulbranson-Judge A, Quinn ME, Walters AE, MacLennan IC, Tybulewicz VL: Syk tyrosine kinase is required for the positive selection of immature B cells into the recirculating B cell pool. J Exp Med 1997, 186:2013-2021.
60. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, Frew E, Scott ML: An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001, 293:2111-2114.
61. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C, Strauch K, Zafari M, Benjamin CD, Tschopp J, Browning JL, Ambrose C: BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001, 293:2108-2111.
62. Su TT, Guo B, Kawakami Y, Sommer K, Chae K, Humphries LA, Kato RM, Kang S, Patrone L, Wall R, Teitell M, Leitges M, Kawakami T, Rawlings DJ: PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002, 3:780-786.
63. Esslinger CW, Wilson A, Sordat B, Beermann F, Jongeneel CV: Abnormal T lymphocyte development induced by targeted overexpression of IkappaB alpha. J Immunol 1997, 158:5075-5078.
64. Boothby MR, Mora AL, Scherer DC, Brockman JA, Ballard DW: Perturbation of the T lymphocyte lineage in transgenic mice expressing a constitutive repressor of nuclear factor (NF)-kappaB. J Exp Med 1997, 185:1897-1907.
65. Gerondakis S, Grossmann M, Nakamura Y, Pohl T, Grumont R: Genetic approaches in mice to understand Rel/NF-kappaB and IkappaB function: transgenics and knockouts. Oncogene 1999, 18:6888-6895.
66. Voll RE, Jimi E, Phillips RJ, Barber DF, Rincon M, Hayday AC, Flavell RA, Ghosh S: NF-kappa B activation by the pre-T cell receptor serves as a selective survival signal in T lymphocyte development. Immunity 2000, 13:677-689.